We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




ARID1A Mutations Linked to ATR Anti-Cancer Drug Sensitivity

By LabMedica International staff writers
Posted on 03 Jan 2017
Print article
Image: The molecular model of the ARID1A protein (Photo courtesy of Wikimedia Commons).
Image: The molecular model of the ARID1A protein (Photo courtesy of Wikimedia Commons).
A team of British cancer researchers suggested in a recent paper that screening for mutations in the ARID1A (AT-rich interactive domain-containing protein 1A) gene could aid in identifying patients with tumors sensitive to the ATR inhibitor class of anti-cancer drugs.

Mutations in ARID1A represent one of the most common molecular alterations in human cancer especially in hard-to-treat tumor types, such as ovarian cancer and stomach cancer, but therapeutic approaches that target these defects are not yet clinically available. Investigators at the Institute of Cancer Research (London, United Kingdom) established a link between mutations in the ARID1A gene and the sensitivity of cancer cells to ATR inhibitor drugs. ATR is a serine/threonine-specific protein kinase that is involved in sensing DNA damage and activating the DNA damage checkpoint, leading to cell cycle arrest. ATR is activated in response to persistent single-stranded DNA, which is a common intermediate formed during DNA damage detection and repair.

The investigators used large-scale genetic screens to identify cancers with mutations in ARID1A that were particularly sensitive to ATR inhibitors. They reported in the December 13, 2016, online edition of the journal Nature Communications that defects in ARID1A sensitized tumor cells to clinical inhibitors of the DNA damage checkpoint kinase, ATR, in cancer cells growing in culture and in mice.

Mechanistically, ARID1A deficiency resulted in topoisomerase 2A and cell cycle defects, which caused an increased reliance on ATR checkpoint activity. In ARID1A mutant tumor cells, inhibition of ATR triggered premature mitotic entry, genomic instability, and apoptosis.

Senior author Dr. Chris Lord, leader of the gene function team at The Institute of Cancer Research, said, "Our research has opened up a potential way of personalizing treatment for cancer by targeting drugs to those patients who will benefit most. We found in cell cultures and in mice that cancers with defective versions of the ARID1A gene are particularly sensitive to a new class of drug called ATR inhibitors. Our research could lead to patients with ARID1A mutant tumors being assessed for whether they respond particularly well to this new class of cancer treatment."

Related Links:
Institute of Cancer Research

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.